🏛️ Verified NIH Record • Updated 2026-05-27
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC (NCT06246110)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Eikon Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).
Location: Southern Cancer Care — Daphne, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- does not have predominantly squamous cell or non-squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.
- is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001.
- prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease, or had major surgery (\< 3 weeks prior to the first dose).
- has completed palliative radiotherapy within 7 days of the first dose of study drug administration.
- has a known history of prior malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years.
- has an active infection requiring therapy.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (38 Sites)
- Southern Cancer Care — Daphne, Alabama
- Ironwood Cancer and Research Center — Chandler, Arizona
- California Cancer Care Associates for Research & Excellence — Fresno, California
- California Research Institute — Los Angeles, California
- University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
- Providence St Joseph Hospital, Center for Cancer Prevention and Treatment — Orange, California
- Sutter Health Institute for Medical Research — Sacramento, California
- Rocky Mountain Cancer — Lone Tree, Colorado
- Bioresearch Partner — Hialeah, Florida
- Memorial Cancer Institute — Hollywood, Florida
- Mid-Florida Hematology and Oncology Center — Orange, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Atlanta Piedmont Hospital — Atlanta, Georgia
- Kaiser Permanente Hawaii — Honolulu, Hawaii
- Illinois Cancer Specialists — Niles, Illinois
- Accelacare of Duly — Tinley Park, Illinois
- Indiana University Cancer Center — Indianapolis, Indiana
- Health Midwest Oncology Associates of Kansas — Overland Park, Kansas
- Cancer Center of Kansas — Wichita, Kansas
- Medstar Franklin Square Cancer Center at Loch Raven Campus — Baltimore, Maryland
- Maryland Oncology — Columbia, Maryland
- Jersey Shore University Medical Center/Meridian Hematology & Oncology — Neptune City, New Jersey
- New York Cancer and Blood Specialists — Babylon, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Weil Cornell Medical Center — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.